A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure

被引：21

作者：

Lepik, Kirill V. ^{[1
]}

Mikhailova, Natalia B. ^{[1
]}

Kondakova, Elena V. ^{[1
]}

Zalyalov, Yuri R. ^{[1
]}

Fedorova, Liudmila V. ^{[1
]}

Tsvetkova, Luibov A. ^{[1
]}

Kotselyabina, Polina V. ^{[1
]}

Borzenkova, Evgeniya S. ^{[1
]}

Babenko, Elena V. ^{[1
]}

Popova, Marina O. ^{[1
]}

Darskaya, Elena I. ^{[1
]}

Baykov, Vadim V. ^{[1
]}

Moiseev, Ivan S. ^{[1
]}

Afanasyev, Boris V. ^{[1
]}

机构：

[1] Pavlov First St Petersburg State Med Univ, Raisa Gorbacheva Mem Inst Children Oncol Hematol, St Petersburg, Russia

来源：

HEMASPHERE | 2020年 / 4卷 / 03期

关键词：

STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; LYMPHODEPLETION; CHEMOTHERAPY; MULTICOHORT; BLOCKADE; THERAPY;

D O I：

10.1097/HS9.0000000000000401

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This single-center prospective clinical trial evaluated the combination of nivolumab plus bendamustine (NB) as a salvage regimen in classical Hodgkin lymphoma patients after failure of nivolumab monotherapy. A total of 30 patients received nivolumab (3 mg/kg) on D1,14 and bendamustine (90 mg/m(2)) on D1, 2 of a 28-day cycle for up to 3 cycles. The ORR was 87% with 57% CR, 30% PR. With median follow-up of 25 months, the estimated 2-year OS was 96,7% (95% CI, 90.2%-100%), PFS was 23,3% (95% CI, 8.2%-38.4%) median PFS was 10.2 months (95% CI, 7.7-14.2 months) with median DOR 6.6 months (95% CI 3.9-11.6 months). Ten patients (33.3%) experienced grade 3 to 4 AE during therapy. Infections were most common AEs of the combined therapy. NB was a highly efficient salvage regimen in relapsed/refractory cHL with a manageable toxicity profile and modest potential for achievement of long-term remission.

引用

页数：7

共 22 条

[1] Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant [J].

Arai, Sally ;

Fanale, Michelle ;

deVos, Sven ;

Engert, Andreas ;

Illidge, Tim ;

Borchmann, Peter ;

Younes, Anas ;

Morschhauser, Franck ;

McMillan, Alex ;

Horning, Sandra J. .

LEUKEMIA & LYMPHOMA, 2013, 54 (11) :2531-2533

[2] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].

Armand, Philippe ;

Engert, Andreas ;

Younes, Anas ;

Fanale, Michelle ;

Santoro, Armando ;

Zinzani, Pier Luigi ;

Timmerman, John M. ;

Collins, Graham P. ;

Ramchandren, Radhakrishnan ;

Cohen, Jonathon B. ;

De Boer, Jan Paul ;

Kuruvilla, John ;

Savage, Kerry J. ;

Trneny, Marek ;

Shipp, Margaret A. ;

Kato, Kazunobu ;

Sumbul, Anne ;

Farsaci, Benedetto ;

Ansell, Stephen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+

[3]

CARREAU NA, 2018, BLOOD S, V132, P1626, DOI DOI 10.1182/BLOOD-2018-99-117672

[4] Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 [J].

Chen, Robert ;

Zinzani, Pier Luigi ;

Lee, Hun Ju ;

Armand, Philippe ;

Johnson, Nathalie A. ;

Brice, Pauline ;

Radford, John ;

Ribrag, Vincent ;

Molin, Daniel ;

Vassilakopoulos, Theodoros P. ;

Tomita, Akihiro ;

von Tresckow, Bastian ;

Shipp, Margaret A. ;

Lin, Jianxin ;

Kim, Eunhee ;

Nahar, Akash ;

Balakumaran, Arun ;

Moskowitz, Craig H. .

BLOOD, 2019, 134 (14) :1144-1153

[5] Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [J].

Chen, Robert ;

Gopal, Ajay K. ;

Smith, Scott E. ;

Ansell, Stephen M. ;

Rosenblatt, Joseph D. ;

Savage, Kerry J. ;

Connors, Joseph M. ;

Engert, Andreas ;

Larsen, Emily K. ;

Huebner, Dirk ;

Fong, Abraham ;

Younes, Anas .

BLOOD, 2016, 128 (12) :1562-1566

[6] Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) [J].

Gordon, Leo I. ;

Hong, Fangxin ;

Fisher, Richard I. ;

Bartlett, Nancy L. ;

Connors, Joseph M. ;

Gascoyne, Randy D. ;

Wagner, Henry ;

Stiff, Patrick J. ;

Cheson, Bruce D. ;

Gospodarowicz, Mary ;

Advani, Ranjana ;

Kahl, Brad S. ;

Friedberg, Jonathan W. ;

Blum, Kristie A. ;

Habermann, Thomas M. ;

Tuscano, Joseph M. ;

Hoppe, Richard T. ;

Horning, Sandra J. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) :684-691

[7] Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma [J].

Green, Michael R. ;

Monti, Stefano ;

Rodig, Scott J. ;

Juszczynski, Przemyslaw ;

Currie, Treeve ;

O'Donnell, Evan ;

Chapuy, Bjoern ;

Takeyama, Kunihiko ;

Neuberg, Donna ;

Golub, Todd R. ;

Kutok, Jeffery L. ;

Shipp, Margaret A. .

BLOOD, 2010, 116 (17) :3268-3277

[8] PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma [J].

Herrera, Alex F. ;

Chen, Robert W. ;

Palmer, Joycelynne ;

Tsai, Ni-Chun ;

Mei, Matthew ;

Popplewell, Leslie L. ;

Nademanee, Auayporn P. ;

Nikolaenko, Liana ;

McBride, Kathryn ;

Ortega, Ricardo ;

Song, Joo Y. ;

Rosen, Steven ;

Kwak, Larry W. ;

Forman, Stephen J. ;

Lee, Hun Ju .

BLOOD, 2019, 134

[9] Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma [J].

Herrera, Alex F. ;

Moskowitz, Alison J. ;

Bartlett, Nancy L. ;

Vose, Julie M. ;

Ramchandren, Radhakrishnan ;

Feldman, Tatyana A. ;

LaCasce, Ann S. ;

Ansell, Stephen M. ;

Moskowitz, Craig H. ;

Fenton, Keenan ;

Ogden, Carol Anne ;

Taft, David ;

Zhang, Qu ;

Kato, Kazunobu ;

Campbell, Mary ;

Advani, Ranjana H. .

BLOOD, 2018, 131 (11) :1183-1194

[10] Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma [J].

Kearl, Tyce J. ;

Jing, Weiqing ;

Gershan, Jill A. ;

Johnson, Bryon D. .

JOURNAL OF IMMUNOLOGY, 2013, 190 (11) :5620-5628

← 1 2 3 →